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Abstract
Introduction:  A  combination  of  antihistamines  and  oral  corticosteroids  is  often  used  to  treat
acute symptoms  of  allergic  rhinitis.
Objective:  To  evaluate  safety  and  efficacy  of  desloratadine  plus  prednisolone  in  the  treat-
ment of  acute  symptoms  of  children  (2--12  years)  with  allergic  rhinitis,  and  to  compare  it  to
dexchlorpheniramine  plus  betamethasone.
Methods:  Children  with  moderate/severe  persistent  allergic  rhinitis  and  symptomatic  (nasal
symptoms score  [0--12]  ≥  6)  were  allocated  in  a  double-blind,  randomized  fashion  to  receive
dexchlorpheniramine  plus  betamethasone  (n  =  105;  three  daily  doses)  or  desloratadine  plus
prednisolone  (n  =  105;  single  dose  followed  by  two  of  placebo)  for  7  days.  At  the  beginning
and end  of  the  evaluation,  the  following  were  obtained:  nasal  symptoms  score,  extra  nasal
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symptoms  score,  peak  nasal  inspiratory  flow,  blood  biochemistry,  and  electrocardiogram.
Ninety-six  children  of  the  dexchlorpheniramine  plus  betamethasone  group  and  98  of  the  deslo-
ratadine  plus  prednisolone  group  completed  the  protocol.
Results:  The  two  groups  were  similar  regarding  initial  and  final  nasal  symptoms  scores,  extra
nasal symptoms  scores  and  peak  nasal  inspiratory  flow.  A  drop  of  76.4%  and  79.1%  for  nasal
symptoms  score,  86.0%  and  79.2%  for  extra  nasal  symptoms  score,  as  well  as  an  increase  of
25.2% and  24.3%  for  peak  nasal  inspiratory  flow  occurred  for  those  treated  with  desloratadine
plus prednisolone  and  dexchlorpheniramine  plus  betamethasone,  respectively.  There  were  no
significant  changes  in  blood  chemistry.  Sinus  tachycardia  was  the  most  frequent  electrocardio-
gram change,  but  with  no  clinical  significance.  Drowsiness  was  reported  significantly  more  often
among those  of  dexchlorpheniramine  plus  betamethasone  group  (17.14%  ×  8.57%,  respectively).
Conclusion:  The  desloratadine  plus  prednisolone  combination  was  able  to  effectively  control
acute symptoms  of  rhinitis  in  children,  improving  symptoms  and  nasal  function.  Compared  to
the dexchlorpheniramine  plus  betamethasone  combination,  it  showed  similar  clinical  action,
but with  a  lower  incidence  of  adverse  events  and  higher  dosing  convenience.
© 2016  Published  by  Elsevier  Editora  Ltda.  on  behalf  of  Associac¸a˜o  Brasileira  de  Otorrino-
laringologia  e  Cirurgia  Ce´rvico-Facial.  This  is  an  open  access  article  under  the  CC  BY  license
(http://creativecommons.org/licenses/by/4.0/).
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Associac¸ão  entre  desloratadina  e  prednisolona  no  tratamento  de  crianc¸as
com  sintomas  agudos  de  rinite  alérgica:  ensaio  clínico  duplo-cego,  randomizado
e  controlado
Resumo
Introduc¸ão:  A  associac¸ão  entre  anti-histamínicos  e  corticosteroides  orais  é  frequentemente
empregada  no  tratamento  de  sintomas  agudos  de  Rinite  Alérgica.
Objetivo:  Avaliar  a  seguranc¸a e  eficácia  da  associac¸ão  desloratadina  +  prednisolona  no  trata-
mento de  sintomas  agudos  de  crianc¸as  (2--12  anos)  com  rinite  alérgica  e  compará-la  à  de
dexclorfeniramina  +  betametasona.
Método:  Crianc¸as  com  rinite  alérgica  persistente  moderada/grave  e  sintomáticas  (escore  de
sintomas nasais  [0--12]  ≥  6)  foram  alocadas  de  modo  duplo-cego  e  randômico  para  receberem
dexclorfeniramina  +  betametasona  (n  =  105;  três  doses  diárias)  ou  desloratadina  +  prednisolona
(n =  105;  dose  única  seguida  por  duas  de  placebo)  por  7  dias.  Ao  início  e  final  da  avaliac¸ão  foram
obtidos: escore  de  sintomas  nasais,  escore  de  sintomas  extra-nasais,  pico  de  fluxo  inspiratório
nasal, bioquímica  sanguínea  e  eletrocardiograma.  Do  total,  96  crianc¸as  do  grupo  dexclorfeni-
ramina +  betametasona  e  98  do  grupo  desloratadina  +  prednisolona  concluíram  o  protocolo.
Resultados:  Os  dois  grupos  foram  iguais  com  relac¸ão  ao  escore  de  sintomas  nasais,  escore  de  sin-
tomas nasais  extra-nasais  e  pico  de  fluxo  inspiratório  nasal  iniciais  e  finais.  Observou-se  queda  de
76,4% e  79,1%  nos  escores  para  escore  de  sintomas  nasais,  de  86,0%  e  79,2%  para  escore  de  sin-
tomas extra-nasais,  assim  como  incremento  de  25,2%  e  de  24,3%  para  o  pico  de  fluxo  inspiratório
nasal para  os  grupos  desloratadina  +  prednisolona  e  dexclorfeniramina  +  betametasona,  respec-
tivamente.  Não  houve  alterac¸ões  significativas  da  bioquímica  sanguínea.  Taquicardia  sinusal  foi
a alterac¸ão  do  eletrocardiograma  mais  encontrada,  mas  sem  significância  clínica.  Sonolência
foi significantemente  mais  referida  entre  os  tratados  com  dexclorfeniramina  +  betametasona  do
que entre  os  desloratadina  +  prednisolona  (8,57%  ×  17,14%,  respectivamente).
Conclusão:  A  associac¸ão  desloratadina  +  prednisolona  foi  capaz  de  controlar  efetivamente  os
sintomas  agudos  de  rinite  em  crianc¸as,  melhorando  sintomas  e  a  func¸ão  nasal.  Na  comparac¸ão
com a  associac¸ão  dexclorfeniramina  +  betametasona,  demonstrou  ac¸ão  clínica  semelhante,  mas
com menor  incidência  de  eventos  adversos  e  maior  comodidade  posológica.
© 2016  Publicado  por  Elsevier  Editora  Ltda.  em  nome  de  Associac¸a˜o  Brasileira  de  Otorrino-
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ecommends  that  treatment  of  allergic  rhinitis  (AR)  is  scaled
ccording  to  the  severity  and  persistence  of  the  disease.1
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In  general,  H1  antihistamines  (anti-H1)  have  been
onsidered  first-line  drugs  in  the  treatment  of  AR  by
xerting  a  significant  effect  on  sneezing,  itching  and  rhi-
orrhea,  and  less  importantly  on  nasal  obstruction.  The
econd-generation  H1  antihistamines  have  been  the  most
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recommended  since  they  cause  fewer  adverse  effects  (seda-
tion,  anticholinergic  action,  among  others)  and  have  a
convenient  dosage  (single  daily  dose).1 Among  the  many
available  in  our  country,  the  following  stand  out:  fexofe-
nadine,  desloratadine,  ebastine,  levocetirizine,  rupatadine
and,  more  recently,  bilastine.
Desloratadine  (descarboethoxyloratadine),  the  primary
metabolite  of  loratadine,  is  a  selective  antagonist  of  second-
generation  H1  receptors.  It  has  a  half-life  of  27  h,  its
absorption  is  not  affected  by  food,  its  metabolism  and  elimi-
nation  are  not  altered  by  age,  race  and  gender,2 and  it  is  not
affected  by  the  simultaneous  administration  of  macrolide
antibiotics,  ketoconazole  and  cyclosporine.3 In  studies  in
patients  with  AR,  desloratadine  was  effective  in  controlling
nasal,  extranasal  symptoms,  even  after  a  single  dose.4--6
Systemic  corticosteroids  (CS)  are  generally  used  when
symptoms  are  not  controlled  with  environmental  or  topical
measures,  or  in  more  severe  cases  with  airway  compromise
or  major  associated  morbidity.1 Compared  to  topical  nasal
CS,  the  systemic  administration  has  the  advantage  of  reach-
ing  all  parts  of  the  nose  and  paranasal  sinuses,  even  in
participants  with  severe  nasal  congestion  and  nasal  polyps.7
Although  the  simultaneous  use  of  anti-H1  and  oral  CS
is  not  recommended  by  ARIA  in  the  treatment  of  AR,
it  has  been  widely  used.  An  auditing  of  sales  (units)  of
pharmaceuticals  in  2015  showed  that  the  association  of
dextrochloropheniramine  and  betamethasone  accounts  for
34.79%  of  sales  of  products  available  in  this  segment  in
Brazil.8 On  the  other  hand,  the  use  of  anti-H1  and  oral  CS
association  in  the  treatment  of  AR  is  rare.
The  objectives  of  this  study  were  to  evaluate  the  efficacy
and  safety  of  desloratadine  +  prednisolone  association  (oral
solution;  DP)  in  the  control  of  acute  nasal  and  extra-nasal
symptoms  in  children  with  moderate-severe  persistent  AR
(PAR)  and  to  compare  its  action  with  the  trade  association
dexchlorpheniramine  +  betamethasone  (syrup;  DB).
Methods
This  prospective,  multicenter,  double-blind,  randomized,
controlled  study  of  parallel  groups  had  the  participation  of
210  children  (2--12  years)  with  moderate/severe  PAR  (1).
The  subjects  exhibited  clinical  features  consistent  with  the
diagnosis  of  AR  (recurrent  nasal  symptoms,  and  sensitiza-
tion  to  airborne  allergens  by  the  presence  of  specific  IgE).  In
addition,  they  had  nasal  symptoms  scores  (NSS)  --  ≥6  during
the  previous  week.  NSS  assess  nasal  obstruction,  rhinorrhea,
sneezing  and  nasal  itching  from  0  (absent)  to  3  (severe)  giv-
ing  a  possible  maximum  score  of  12  points.  All  subjects’
parents/guardians  signed  the  informed  consent  document.
Patients  on  specific  allergen  immunotherapy,  those  with
previous  treatment  in  the  last  15  days  with  oral  corticoste-
roids  or  topical  nasal  or  oral  antihistamines,  those  with  a
chronic  disease  (hematopoietic,  cardiovascular,  renal,  neu-
rological,  psychiatric  and  autoimmune  disorders)  as  well
as  those  with  uncontrolled  asthma,  chronic  rhinosinusitis
and/or  anatomical  abnormalities  of  the  upper  airways,  were
not  admitted  to  the  study.
During  selection  (Visit  0  --  V0),  patients  were  evaluated
clinically  and  scored  according  to  the  NSS,  and  the  extra-
nasal  symptoms  score  --  ExNSS.  This  evaluates  itchy  eyes,
P
C
an  children  635
tchy  palate,  ocular  hyperemia  and  tearing,  and  is  scored
rom  0  (absent)  to  3  (severe),  for  a  maximum  possible  score
f  12  points.  Furthermore,  a  peripheral  blood  sample  was
ollected  for  CBC,  transaminase,  urea,  creatinine,  biliru-
in  dosage,  and  an  electrocardiogram  (ECG)  was  performed.
hen  subjects  returned  at  day  5  (±2),  if  there  were  no
aboratory  abnormalities,  patients  were  allocated  in  ran-
om  order,  in  double-blind  fashion,  to  the  treatment  groups,
ccording  to  the  active  principle:  DP  or  DB.  At  this  visit,  they
ere  clinically  reevaluated,  and  those  over  six  years  of  age
nderwent  the  measurement  of  peak  nasal  inspiratory  flow
PNIF)  (V1).  After  receiving  the  guidelines  on  the  daily  filling
f  nasal  symptoms  and  the  registration  of  possible  adverse
vents,  patients  were  released  and  told  to  return  in  7  (±2)
ays  (V2)  when  they  underwent  all  clinical  and  laboratory
ests  again.
reatment  regimens
atients  were  randomized  by  electronic  CRF  (Case  Report
orm)  at  the  time  of  enrollment  in  the  study  using  the
riterion  of  blocks  of  six  treatments,  with  three  being  DP
nd  three  DB,  and  received  the  drugs  as  follows:  (a)  DP
-  desloratadine  (0.5  mg/mL)  and  prednisolone  (4  mg/mL)
ombined  in  oral  solution,  or  DB  --  commercially  available
Celestamine®,  Mantecorp,  Brazil)  a  combination  of  dex-
hlorpheniramine  maleate  (0.4  mg/mL)  and  betamethasone
0.05  mg/mL)  syrup.  Children  under  6  years  who  started
reatment  with  the  formulation  of  DP  received  2.5  mL  orally
vial  A)  complemented  by  two  other  oral  doses  of  placebo
vials  B  and  C),  at  intervals  of  8  h.  Patients  treated  with  DB
eceived  three  oral  doses  of  2.5  mL  (vials  A,  B  and  C)  also
t  8-h  intervals.  Patients  older  than  6  years  received  dou-
le  the  dose  (5  mL)  employing  the  same  distribution  of  vials.
ials  of  both  treatment  regimens  and  those  of  placebo  were
dentical,  and  the  same  vehicle  was  used,  so  as  to  have  the
ame  flavor.  The  vials  were  labeled  according  to  the  recom-
endations  by  ANVISA.9 Randomization  codes  were  broken
nly  after  analyzing  the  data.
aily  nasal  symptoms,  self-assessment
uestionnaire  and  report  of  adverse  events
hose  responsible  for  the  patients  were  instructed  to  fill
ut  the  diary  of  symptoms  (sneezing,  itching,  runny  nose
nd  nasal  obstruction)  with  respect  to  its  interference
n  daily  activities  (0  =  no  symptoms,  1  =  mild  symptoms,
 =  symptoms  that  interfere  with  daily  routine,  but  not  sleep;
nd  3  =  symptoms  that  interfere  with  sleep).  The  sum  of
cores  was  the  score  of  each  day  of  treatment.
In  addition,  those  responsible  for  the  patients  were  also
sked  to  answer  the  self-assessment  questionnaire  regarding
he  use  of  prescribed  medication  (did  not  take,  took  25%,
ook  50%,  took  75%,  took  everything  --  100%)  on  each  day  of
reatment,  as  well  as  on  the  presence  of  any  adverse  events
uch  as  somnolence,  headache,  tremors,  among  others.eak  nasal  inspiratory  flow  (PNIF)
hildren  over  six  years  underwent  PNIF  at  Visit  1  and
t  the  end  of  treatment.  PNIF  measurements  (In-Check®,
6 Wandalsen  GF  et  al.
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Table  1  Characteristics  of  children  with  moder-
ate/severe  persistent  allergic  rhinitis  at  admission,
according  to  the  treatment  regimen  received:  DP
(desloratadine  +  prednisolone)  or  DB  (dexchlorpheni-
ramine  +  betamethasone)  --  treatment  intention.
Characteristic  DP  (n  =  105)  DB  (n  =  105)  Fisher  p
Males  55  54  1.00
Age (years)
2--6 42  32  0.19
>6 63  73
Concomitant  medical
complaintsa
61  54  0.41
Concomitant
medication
84 96  0.028
Baseline  score  of
nasal  symptoms
9.0  (2.0)b 9.0  (2.1)b 0.89
Baseline  scores  of
extra-nasal
symptoms
5.6  (3.2)b 5.3  (3.1)b 0.51
a Associated complaints, sinusitis, asthma and headache.
b Standard deviation.
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Figure  1  Progression  of  score  (average)  of  nasal  and
extranasal  (Ex)  symptoms  according  to  the  treatment  group:
desloratadine  +  prednisolone  (DP  and  DPEx,  respectively)  or
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s36  
lement-Clarke,  England)  were  conducted  after  patients
lew  their  noses,  in  triplicate  recording  the  highest  value
ccording  to  existing  recommendations.10
ample  calculation
ecause  it  is  a  non-inferiority  study  of  parallel  groups,  we
mployed  as  the  primary  variable  the  change  of  NSS,  hav-
ng  admission  as  basis.  For  this  purpose,  we  estimated  a
0%  reduction  of  NSS  after  treatment,  and  considering  the
aximum  difference  of  0.5  point  between  the  two  treat-
ent  groups,  and  standard  deviation  of  0.5  point,  with  an
lpha  error  of  5%,  and  95%  test  power  would  be  necessary
o  include  86  patients  per  group.  Estimating  losses  of  up  to
0%  of  patients  included,  the  total  number  of  patients  to  be
ncluded  is  210;  105  in  each  treatment  group.
tatistical  analysis
ccording  to  the  nature  of  the  variables  analyzed,  para-
etric  or  non-parametric  tests  were  used,  fixing  the  level
f  rejection  of  the  null  hypothesis  at  5%.  For  the  analysis
o  be  carried  out,  we  used  SAS  system  (Statistical  Analysis
ystem),  version  9.1.3.
The  protocol  was  approved  by  the  Ethics  Committee  of
he  Universidade  Federal  de  São  Paulo  --  Escola  Paulista  de
edicina  and  Hospital  São  Paulo,  as  well  as  that  of  all  the
enters  involved,  and  it  was  recorded  in  ClinicalTrials.org
RS  under  number  NCT  01529229.  All  guardians  signed  the
nformed  consent,  and  children  older  than  6  years  the  assent
orm.
esults
ne-hundred  and  ninety-five  patients  completed  the  study
DP  n  =  98  and  DB  n  =  97).  Two  patients  from  the  DB  group,
nd  one  of  the  DP  group  were  excluded  due  to  adverse
vents,  three  of  DB  and  three  of  the  DP  were  eliminated
ue  to  poor  compliance,  one  of  the  DB  group  and  one  of  the
P  group  were  excluded  due  to  protocol  violation,  one  of  DB
nd  two  of  DP  group  abandoned  the  study,  and  one  patient
f  the  DB  group  withdrew  the  informed  consent.
Table  1  summarizes  the  main  clinical  characteristics  of
he  patients  according  to  the  received  treatment  regimen.
e  found  that  except  for  the  use  of  additional  drugs  that
ere  significantly  higher  among  those  in  the  DB  group,  the
wo  groups  were  similar,  especially  regarding  NSS,  ExNSS,
nd  laboratory  abnormalities.
Patients  treated  with  DP  showed  a  reduction  of  76.4%
f  NSS;  86.0%  of  ExNSS,  and  an  increase  of  25.2%  of  PNIF
ompared  to  baseline  (Table  2).  Those  treated  with  DB
howed  a  reduction  of  79.1%  of  NSS;  79.2%  of  ExNSS,  and
4.3%  increase  in  PNIF  compared  to  baseline  (Table  2).  The
omparative  analysis  of  these  parameters  between  the  two
reatment  regimens  either  at  the  beginning  or  at  the  end
id  not  show  significant  differences.
In  Fig.  1,  we  observed  average  values  of  reduction  in
SS  and  ExNSS  regarding  the  first  day  of  evaluation,  dur-
ng  the  7  days  of  monitoring,  according  to  the  two  treatment
roups.  We  found  that  the  two  regimens  provided  significant
eduction,  but  no  significant  differences  between  them.
t
a
w
hexchlorpheniramine  +  betamethasone  (DB  and  DBEx,  respec-
ively)  according  to  different  days.
The  treatment  regimen  was  followed  by  almost  all  the
atients  in  both  study  groups.  When  asked  about  the
esponse  obtained  after  the  treatment  received,  there  was
o  significant  difference  between  the  frequency  of  patients
ho  reported  being  much  better/better  after  the  treatment
eceived  (Table  3).
Safety  assessment  was  carried  out  taking  the  presence
f  significant  clinical  changes  as  basis.  Only  one  patient
f  the  DP  group  (#  40)  had  changes  in  the  cardiovascular
ystem,  with  no  significant  clinical  implications.  In  addi-
ion,  blood  biochemistry  revealed  no  patient  abnormalities
fter  treatment  (data  not  shown).  Regarding  ECG  findings,
e  found  that  18  from  the  DB  group  and  29  from  the  DP
ad  changes  at  the  beginning  and/or  end  of  treatment.  For
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Table  2  Average  score  (standard  deviation)  of  nasal  symptoms  (NSS),  of  extra-nasal  symptoms  (ExNSS)  and  of  peak  nasal
inspiratory flow  (PNIF)  of  children  with  moderate/severe  persistent  allergic  rhinitis  at  admission  (V1)  and  after  treatment  (V2;
7 ±  2  days)  with  DP  (desloratadine  +  prednisolone)  or  DB  (dexchlorpheniramine  +  betamethasone).
DP  (n  =  98)  DB  (n  =  97)
V1  V2  V1  −  V2  V1  V2  V1  −  V2
NSS  8.9  (2.0) 2.1  (2.3) 6.8 9.1  (2.1) 1.9  (2.3) 7.2
ExNSS 5.7  (3.1)  0.8  (1.2)  4.9  5.3  (3.2)  1.1  (2.2)  4.2
DP (n  =  61)  DB  (n  =  70)
V1  V2  V1  −  V2  V1  V2  V1  −  V2
Peak  nasal  inspiratory  flow  (L/min)
PNIF  70.3  (23.9)  83.6  (26.3)  13.3  64.5  (21.9)  80.3  (25.0)  15.8
Mann--Whitney.
NSS, ExNSS and PNIF-V1: DP = DB; V2: DP = DB; V1 − V2: DP = DB.
DP and DB--NSS, ExNSS and PNIF: V1 > V2 -- p < 0.05.
Table  3  Global  assessment  of  the  participant  regarding
received  treatment:  DP  (desloratadine  +  prednisolone)  or  DB
(dexchlorpheniramine  +  betamethasone).
Assessment  of  participant DP  DB
n  (%) n  (%)
Much  better/better  96  (98.0)  94  (96.9)
Unchanged/worse  2  (2.0)  3  (3.1)
Table  4  Adverse  events  reported  by  at  least  1%
of patients,  according  to  the  treatment  group:
desloratadine  +  prednisolone  (DP)  or  dexchlorpheni-
ramine  +  betamethasone  (DB).
Adverse  event  DP  DB  p
n (%) n  (%)
Excitement  1  (0.95)  2  (1.90)  0.28
Increased  appetite  2  (1.90)  5  (4.76)  0.12
Heart burn  2  (1.90)  1  (0.95)  0.28
Headache  0  (0.0)  3  (2.86)  0.03
Diarrhea  2  (1.90)  3  (2.86)  0.32
Pain 2  (1.90)  0  (0.0)  0.08
Abdominal  pain  2  (1.90)  3  (2.86)  0.32
Epistaxis  3  (2.86)  0  (0.0)  0.03
Breathlessness  0  (0.0)  2  (1.90)  0.08
Fever 0  (0.0)  4  (3.81)  0.02
Insomnia  3  (2.86)  2  (1.90)  0.32
Irritability  1  (0.95) 2  (1.90)  0.28
Nausea 0  (0.0) 2  (1.90) 0.08
Somnolence  9  (8.57)  18  (17.14)  0.03
Dizziness  1  (0.95)  2  (1.90)  0.28
Cough 7  (6.60)  5  (4.76)  0.27
Vomit 3 (2.86)  2  (1.90)  0.32
ECG changes  6  (6.1)  11  (11.3)  0.52
A
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bTotal 98  (100.0)  97  (100.0)
Fisher’s exact test -- p = 0.682.
all  patients,  these  changes  were  not  followed  by  significant
clinical  symptoms,  and  were  considered  irrelevant:  mainly
sinus  tachycardia,  physiological  sinus  arrhythmia,  intraven-
tricular  conduction  delay.  Six  patients  in  the  DP  group  and  11
in  the  DB  group  presented  changes  at  the  end  of  the  study,
but  had  normal  ECG  tracing  at  the  beginning,  a  difference
that  was  not  significant  (p  =  0.52).
As  for  reported  adverse  events,  somnolence  was  the  most
reported,  being  significantly  higher  among  those  treated
with  DB  (Table  4).  Headache  and  fever  had  similar  occur-
rences.  However,  epistaxis  was  reported  significantly  more
often  among  DP  patients  (Table  4).  All  these  events  were
classified  as  not  severe  (Table  4).
Discussion
Both  treatment  regimens  were  effective  in  controlling
acute  symptoms  of  children  and  adolescents  with  moder-
ate/severe  PAR,  revealed  by  the  reduction  of  NSS  and  ExNSS,
as  well  as  the  increase  of  PNIF  (Table  2).  It  is  worth  noting
that  the  patients  analyzed  had  a  picture  of  AR  of  moderate
to  severe  intensity,  which  often  makes  the  treatment  more
challenging.1
Although  the  reduction  of  NSS  compared  to  baseline  val-
ues  was  76.4%  for  those  treated  with  DP,  and  79.1%  for
those  treated  with  DB,  there  were  still  patients  who  did
not  achieve  full  control  of  nasal  and  extra-nasal  symptoms.
AILA  study  (Allergies  in  Latin  America)  conducted  to  deter-
mine  the  prevalence  of  AR  in  the  population  of  some  Latin
i
s
s
iFisher’s exact test
Italic type -- significantly different.
merican  countries  documented  that  many  patients  identi-
ed  as  having  AR  frequently  changed  treatment  regimens
ecause  they  considered  them  ineffective,  and  the  use
f  combination  of  drugs  of  different  classes  was  common
mong  them.11 A  similar  finding  was  observed  by  other
esearchers.12,13
The  objective  measure  of  nasal  patency  was  performed
y  measuring  PNIF,  an  easily  obtainable  parameter  that
s  reproducible  and  low  cost.  PNIF  measures  have  proven
ensitive  to  discriminate  patients  with  different  levels  of
everity  of  rhinitis  and  useful  for  various  purposes,  such  as
n  the  objective  evaluation  of  response  to  treatments  for
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llergic  rhinitis.10 Both  treatment  regimens  provided  signif-
cant  increase  in  nasal  patency  with  an  increase  in  mean
alues  of  PNIF  close  to  25%  of  baseline.  This  finding  can  be
onsidered  clinically  relevant.  As  a  comparison,  nasal  provo-
ation  studies  consider  variation  in  PNIF  values  of  the  order
f  20%  for  defining  relevant  nasal  obstruction  and  comple-
ion  of  the  test.14,15
Regarding  safety  evaluation  of  treatment  regimens  used,
e  found  that  the  frequency  of  drowsiness  among  those
reated  with  DB  was  two  times  higher  than  that  on  those
reated  with  DP  (Table  4).  In  addition,  although  the  number
f  patients  with  ECG  changes  at  baseline  was  higher  among
hose  in  the  DP  group,  this  difference  disappeared  at  the
nd  of  the  study  when  only  six  patients  of  DP  group  and  11
f  the  DB  group  still  had  such  changes.
Although  first-generation,  or  classic,  anti-H1  has  been
sed  in  the  treatment  of  allergic  diseases  since  the  1940s,
afety  studies  are  scarce  and  more  recent.  These  drugs
ave  been  developed  from  the  same  base  molecule,  simi-
ar  to  the  muscarinic  cholinergic  antagonists,  tranquilizers,
ntipsychotics  and  anti-hypertensive  agents,  and  due  to
heir  low  selectivity  for  H1  receptors,  they  interact  with
eceptors  of  other  active  amines  causing  antimuscarinic,
nti--adrenergic  and  anti-serotonin  effects.  Since  they
ross  the  blood-brain  barrier  easily,  they  bind  to  brain  H1-
eceptors  and  interfere  with  neurotransmitter  function  of
istamine  causing  drowsiness,  sedation,  fatigue,  decreased
eadiness,  worsening  of  cognitive  function,  memory  and
sychomotor  performance.16 This  explains  the  higher  preva-
ence  of  drowsiness  among  the  subjects  in  the  DP  group,
ince  dexchlorpheniramine  is  representative  of  the  classic
r  first  generation  anti-H1.17
It  was  from  1980  on  that  the  second  generation  of
nti-H1  emerged  and  started  being  used  in  large  scale,
ith  no  side  effects  previously  associated  with  the  first-
eneration  agents.  However,  the  occurrence  of  cardiotoxic
ffects  was  associated  with  some  of  them:  terfenadine  and
stemizole.17 This  fact  was  documented  to  be  due  to  compe-
ition  for  hepatic  metabolic  pathway,  the  cytochrome  P450
ystem,  by  those  drugs,  ketoconazole,  macrolide  antibi-
tics,  and  other  agents,  which  would  result  in  a  high
irculating  levels  of  that  anti-H1  agent  that  were  potentially
ardiotoxic.  This  fact  lead  to  the  replacement  of  these  anti-
1  agents  by  newer  agents  of  similar  chemical  structure  that
ad  none  of  these  adverse  effects,  but  had  the  same  power
f  action.17
Another  important  fact  is  the  indiscriminate  use  of  first
eneration  anti-H1  agents  among  infants  and  children  that
ame  to  be  twice  greater  than  drugs  of  the  second  gen-
ration.  This  widespread  use  for  many  years  created  the
alse  impression  that  they  were  as  safe  as  the  second
eneration.16 In  addition,  many  doctors  prescribe  them  for
heir  sedative  effect,  believing  that  patients  will  have  a
etter  sleep.  This  idea  proved  to  be  wrong  since  these
rst-generation  anti-H1  agents  prevent  the  patient  from
eaching  the  REM  stage  of  sleep,  making  it  ineffective.18,19
he  current  consensus  does  not  recommend  the  use  of  first-
eneration  anti-H1  for  the  treatment  of  allergic  rhinitis,  and
ecommends  the  use  of  second-generation  anti-H1  agents
or  their  greater  safety  and  lower  incidence  of  adverse
vents.19
1Wandalsen  GF  et  al.
onclusion
n  conclusion,  although  both  treatment  regimens  have  pro-
ided  effective  control  of  the  symptoms  of  PAR,  DP  showed
o  be  more  advantageous  due  to  its  convenient  dosage
chedule  (once  a  day)  and  lower  frequency  of  adverse
ffects.
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